Global Sleep Symposium Features Inactivators™ Sleep Mask for Performance-Driven Sleep Support as America Faces an Unprecedented Era of Stress
ATLANTA--(BUSINESS WIRE)--Apr 17, 2025--
As April marks National Stress Awareness Month, Atlanta-based sleep performance company The Inactive Company, is showcasing its innovative sleep mask, Inactivators™, as a science-backed solution to help combat stress by promoting deeper, restorative sleep.
Developed over more than a year, largely in collaboration with hospitality and performance brands such as Equinox Hotels, the National Football League, and Collegiate Football properties, The Inactive Company is launching nationally in conjunction with the Global Sleep Symposium. Inactivators feature a patented five-layer design. They are not just sleep masks; they act as a performance tool for anyone looking to enhance their sleep quality, especially during periods of heightened anxiety and stress.
'Stress and sleep are closely interconnected. Each affects the other, and both can be improved with the right tools,' says Lori Oliver, co-founder of The Inactive Company. 'Inactivators are designed to support your sleep physiology, allowing your body to restore, recover, and recharge each night.'
Featuring 100% light blockage, cooling materials, and a customizable ergonomic fit, Inactivators facilitate deeper and more restorative sleep. By tackling common stress-related sleep issues like restlessness and temperature regulation, the mask offers relief for individuals who lie awake with racing thoughts.
'Sleep is essential for everything—memory, mood, immune system,' notes Jill MacRae, co-founder of The Inactive Company. 'This month aims to remind people that managing stress begins with prioritizing rest.'
The five-layer Inactivators mask includes:
More than 60 million Americans suffer from chronic sleep disorders, and only one in three adults gets the recommended 7 to 9 hours of sleep each night. Even mild sleep deprivation can lead to increased stress, cognitive decline, and long-term health risks like high blood pressure and obesity.
Inactivators Take Center Stage at the Global Sleep Symposium
The performance sleep mask will be featured at the second annual Global Sleep Symposium on May 1 in New York City, where sleep experts, wellness leaders, and tech pioneers will gather to explore the future of sleep innovation and technology.
'Our presence at the Symposium is timely. The country and the world are facing unprecedented levels of sleep deprivation. However, as we prepare to hear from some of the brightest minds in health, we feel incredibly optimistic about our Inactivators product and the opportunity to awaken the sleep superpowers inherent in people,' adds Oliver.
About The Inactive Company
The Inactive Company is a sleep performance brand dedicated to developing technology and tools that enhance rest and recovery for everyone. Its innovative sleep mask, Inactivators™, is a scientifically backed solution to improve sleep and is trusted by professional and collegiate sports organizations. By emphasizing the science of sleep and the power of intentional design, the company aims to create a world of well-rested individuals. For more information, visit https://inactiveco.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250417824043/en/
CONTACT: Jason Gilbreth
[email protected]
(847) 894-8112
KEYWORD: UNITED STATES NORTH AMERICA NEW YORK GEORGIA
INDUSTRY KEYWORD: GENERAL HEALTH MEDICAL DEVICES OTHER HEALTH HEALTH FITNESS & NUTRITION
SOURCE: The Inactive Company
Copyright Business Wire 2025.
PUB: 04/17/2025 09:08 AM/DISC: 04/17/2025 09:08 AM
http://www.businesswire.com/news/home/20250417824043/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
Novel T Cell Measurement System by Novoviah Pharmaceuticals Demonstrates High Accuracy for Clinical Disease Detection and Monitoring of Celiac Disease
BRISBANE, Australia, June 10, 2025--(BUSINESS WIRE)--Novoviah Pharmaceuticals announces that their novel clinical platform technology for detecting and monitoring disease by measuring immune reactivity has been successfully tested in Celiac Disease, with results published in Gastroenterology. The NovoleukinTM test platform, developed specifically for clinical use, measures T Cell reactivity in fresh whole blood after 24-hour in vitro stimulation with a target antigen. The proprietary technology boosts T Cell activity after blood collection, enabling accurate cytokine biomarker measurement and comparison with unstimulated controls. This can be used to monitor disease reactivity status and the effectiveness of prospective therapeutics. Originally developed for multi-center clinical trials, the NovoleukinTM system has potential for broader clinical use. Its utility and performance were demonstrated in collaboration with WEHI researchers who analyzed blood samples from 181 volunteers to identify the presence and assess the severity of celiac disease. The results show high sensitivity (90%) and specificity (95%) in detecting celiac disease, even in patients following a strict gluten free diet which normally confounds traditional diagnostic methods. The test detects as few as one gluten-specific T lymphocyte in one milliliter of blood or one per million CD4+ T cells. This level of sensitivity in a straightforward blood test is a landmark technical achievement and promises to impact patient care in many fields and accelerate immunotherapy and vaccine development. Associate Professor Jason Tye-Din, Head of WEHI's Celiac Research Laboratory and a gastroenterologist at the Royal Melbourne Hospital, highlighted the test's promise for simplifying diagnosis and removing a significant barrier in current diagnostics. "By stimulating T cells after a blood draw, patients can avoid the need to return to gluten and the suffering that often comes with that – for the sole purpose of diagnosis. That is a major step towards improving outcomes for patients." The test was also predictive of patient responses during gluten challenge protocols, underscoring its utility in stratifying patients for clinical research and tailoring therapeutic strategies. Dr Robert Anderson, co-founder of Novoviah Pharmaceuticals, current President of the International Society for the Study of Celiac Disease and a practicing gastroenterologist, said the study highlights the potential of practical, blood-based T cell diagnostics in clinic and for clinical trials. "The test is designed for ease of use in the clinical setting. It can be prepared without specialist equipment and then sent for highly sensitive laboratory analysis. The protocol is simple and reproducible enabling easy rollout across multiple sites," Dr Anderson said. The Novoleukin test's ability to detect disease and measure changes in immune response has proven invaluable in the developmental journey for drug developers. "Non-invasively monitoring T cell reactivity opens the door to transformative clinical applications, particularly in drug development," Dr Anderson added. "The platform is already being used by leading biopharma partners to evaluate immune responses during celiac disease clinical trials, offering real-time insights into treatment efficacy." Novoviah is actively expanding the diagnostic applications of the Novoleukin platform across additional immune-mediated diseases, including viral infection, autoimmune conditions and some cancers, aiming to bring T cell-guided insights to clinical and research settings. About Novoviah Pharmaceuticals Novoviah is a Brisbane-based biotechnology company established in 2020 to develop and supply a new best in-class NovoleukinTM antigen-specific T cell testing platform for clinical trials and explore its broader application in clinical care. Novoviah is committed to advancing sensitive and reliable clinical tests for antigen-specific T cells to support drug developers, researchers, clinicians and patients needing better treatments and diagnosis. Find out more at About WEHI (Walter and Eliza Hall Institute of Medical Research) WEHI is where brilliant minds collaborate and innovate to make life-changing scientific discoveries that help people live healthier for longer. Our medical researchers have been serving the community for more than 100 years, making transformative discoveries in cancer, infection and immunity, and lifelong health. WEHI brings together diverse and creative people with different experience and expertise to solve some of the world's most complex health problems. With partners across science, health, government, industry, and philanthropy, we are committed to long-term discovery, collaboration, and translation. At WEHI, we are brighter together. Find out more at View source version on Contacts Novoviah Pharmaceuticalskylieell@ +61413496222 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
42 minutes ago
- Business Wire
Wisp Names Jennifer Peña as Chief Medical Officer to Support Integrated Women's Telehealth
NEW YORK--(BUSINESS WIRE)-- Wisp, the largest pure play women's telehealth company in the U.S. focused on providing sexual and reproductive health solutions to more than 1.5 million customers, today announced the appointment of Jennifer Peña, MD, as the company's Chief Medical Officer. Dr. Peña will have a crucial role in driving Wisp's commitment to being the one-stop-shop for all women's health needs, as the company continues to scale new and existing offerings. As CMO, Dr. Peña will spearhead Wisp's clinical strategy, quality, and safety programs, aligning telehealth operations with the company's broader business goals. She will oversee clinical care delivery, ensuring regulatory compliance and high standards of patient care, while guiding product development and expanding protocols for new verticals. Dr. Peña will mentor and grow a multidisciplinary clinical team, establish KPIs to benchmark performance, and collaborate cross-functionally to integrate clinical insight into Wisp's innovation and execution. As a clinical expert, she will serve as a key advisor to internal and external stakeholders as Wisp accelerates its growth. 'Wisp is committed to delivering clinical excellence and expanding access to high-quality care for women nationwide,' said Monica Cepak, CEO of Wisp. 'We have already built a trusted platform serving over 1.5 million women to meet all of their health needs. As we continue to grow and remain the leading one-stop shop for women's health, Dr. Peña's clinical expertise, across traditional clinics and telehealth, will help us push the boundaries of what's possible in virtual care. Her leadership will be crucial in building the next chapter of Wisp as we double down on our commitment to bringing innovation, accessibility, and quality care into the women's health space.' Dr. Peña brings 20 years of clinical and leadership experience across the healthcare ecosystem. As a board-certified internal medicine physician, she previously served as Medical Director for Oscar Health and Chief Medical Officer for Nurx, K Health, and Vault Health, where she led teams that delivered high-quality, tech-enabled care to diverse populations. Before that, she served as a U.S. Army physician and White House physician. Dr. Peña earned her MD from the University of Pittsburgh School of Medicine and her undergraduate degree from Yale University. 'Wisp is redefining access to sexual and reproductive health with clinical excellence and unmatched convenience,' said Dr. Jennifer Peña, Chief Medical Officer at Wisp. 'I'm thrilled to join a company that is breaking down barriers and reimagining what care looks like, whether that's delivering at-home STI testing, affordable BV treatment, effective UTI prevention or evidence-based menopause support. We're not just offering telehealth; we're building a movement to destigmatize women's health and set a new, human-centered standard for virtual care." ABOUT WISP: Wisp is the largest pure play women's telehealth company in the U.S. focused on providing sexual and reproductive health solutions to its more than 1.4 million patients in all 50 states. Offering discreet treatments online with a comprehensive selection of first-to-market products and telehealth services, Wisp has solidified itself as the one-stop shop for all women's health needs. Wisp is committed to making women's healthcare more inclusive, cost-effective, and accessible for all, addressing all stages of her healthcare journey, from her birth control, to fertility, menopause, STI diagnostics, weight care and more. Wisp has been named Fast Company's Most Innovative Companies of 2023 and Inc.'s Best in Business in 2024. Wisp is a growing and profitable company and is majority-owned by WELL Health Technologies Corp. To learn more, please visit or follow @hellowisp on Facebook, Instagram, TikTok and YouTube.
Yahoo
42 minutes ago
- Yahoo
NeuroSigma Announces Notice of Allowance for Patent Protecting Monarch eTNS System in China
LOS ANGELES, June 10, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company commercializing the Monarch external Trigeminal Nerve Stimulation (eTNS) device for treating attention-deficit hyperactivity disorder (ADHD), today announced a notice of allowance in China for a patent protecting the Monarch eTNS System. The patent, titled Pulse Generator for Trigeminal Nerve Stimulation, protects certain embodiments of NeuroSigma's core eTNS technology, including its second-generation Monarch device. The patent was allowed by China's National Intellectual Property Administration on May 27, 2025. In 2022, NeuroSigma licensed rights to the Monarch eTNS System for treating ADHD in China to Ignis Therapeutics, a leader in the development of novel therapeutics for central nervous system (CNS) conditions. 'As NeuroSigma continues to grow and work with our partners at Ignis, China will be a critical market for the Monarch eTNS System,' said Colin Kealey, M.D., President and CEO of NeuroSigma. 'This patent protects our second-generation Monarch device in China and significantly strengthens the company's intellectual property position.' "NeuroSigma's Monarch eTNS System is a highly innovative and effective therapy for ADHD,' added Tom Paschall, Director of NeuroSigma and CEO of Checkmate Capital. 'China is one of the largest and most important markets in the world for new CNS therapies. With this patent award, the Monarch device will benefit from robust intellectual property protection, which, we believe, will facilitate commercialization in this key market.' About NeuroSigma NeuroSigma is a Los Angeles, California-based bioelectronic medical device company developing technologies to transform medical practice and patients' lives. The company's lead product is the Monarch eTNS System, which is the first non-drug treatment for pediatric ADHD cleared by the FDA. Pipeline indications for the Monarch eTNS System include neurodevelopmental disorders such as autism spectrum disorder (ASD), learning disabilities, and epilepsy. NeuroSigma has received Breakthrough Device Designation for the Monarch eTNS System from the FDA in drug-resistant epilepsy. For more information about NeuroSigma, please visit For more information on the Monarch eTNS System, please visit Contact:Colin Kealey, M.D., President of NeuroSigma at CKealey@
